FROZEN TISSUE ARRAY TECHNOLOGY FOR SIMULTANEOUS ANALYSIS OF RNA, DNA & PROTEINS

The advent of frozen tissue array technology revolutionized clinical molecular analysis, immunohistochemistry and other methodologies with a more powerful proteomic substrate. The technology allows a fast-paced, cost-efficient, intense through-put analysis of numerous tissue layers at protein and genome levels. Micro-arraying numberless small tissue samples from a variety of conditions on an individual historical slide allow in-depth throughput analysis of compound specimens simultaneously.

Different types of malignancies, at various phases of disease development, can be investigated at one platform, in the same status as well as reduced labor-intensive and cost-saving techniques. It permits synchronized analysis of microcosm targets of genes and proteins under homogeneous states on one glass slide and also renders optimal preservation and retrieval of tissue samples. With automated frozen tissue array data, retrospective and progressive analysis offers a broad spectrum of potential uses in research, cancer treatment, prognostic oncology and drug invention.

Benefits of Frozen Tissue Array Technology

• This technique has equipped medical experts with a powerful tool to probe and examine diseases at an early phase. It packs multiple tissue samples into a single column. Smaller sections may be separated from the array chunk depending on the size of the core. Multifarious tissue cores arranged on one single slide facilitate multiplex analysis in the shortest space of time.

• Frozen tissue array has a variety of applications such as RNA analysis in situ hybridization, immunohistochemistry and joint study of unvaryingly and optimally ensconced genes and proteins from a series of tumor representatives. The technology will lead to a breakthrough in the multidisciplinary tumor pathobiology, and the pinpointing or validation of new markers for therapy. Given that it uses traces of the reagent to study a single slide, it provides cost-efficiency for immunohistochemistry or in situ hybridization methodologies.

• The new tissue microarray technology analyzes up to 1000 tumor samples rendering superior quality control and assurance in immunohistochemistry. They portray the antibody benchmarks on one slide, which optimizes the visible high or low signal intensities.

• Experimental homogeneity

• Leads to amplification and preservation of sparse tissue samples

• Saves on assay volume

• Decreases the lot of slides needed

• Higher Throughput

• Allows automation and computerized mapping of data

• Provides efficiency in fixation-sensitive reagents

• The ability to fix one tissue array slide in a specific way to the corresponding methodology used includes pinpoint-accuracy in setting DNA, RNA, or protein targets

Advanced Tissue Microarray

The new tissue microarray facilitates the analysis of 100 to 1,000 tumor sections on one slide. The technology renders high through-put analysis of DNA, RNA, and proteins in a broader cohort. Making tissue microarrays occurs via coring tissues extracts from paraffin-embedded donor blocks and banding them together into a single stratum. Paraffin-embedded tissue samples undergo antigen denature in proteins or mRNA deterioration caused by the fixation and attaching process. Researchers have postulated a new technique for making tissue microarrays with non-fixed, pristine frozen tissue. Sections sliced from the tissue microarrays offer ideal target materials for the analysis of DNA, RNA, and proteins with every part fixed in a way precise to match the technique employed.

Conclusion

The significant constraints in molecular lab analysis of tissue samples revolved around the laborious nature of the processes, poor accessibility of reagents and shortfalls in patient samples. New microarray techniques have evolved to redress these issues.